Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Demystifying Neurosarcoidosis and Informing Prognosis

Demystifying Neurosarcoidosis and Informing Prognosis Opinion Editorial heterogeneity: re-analysis of individual participant hydrochloride therapy after stroke or transient 13. Hijazi Z, Oldgren J, Lindbäck J, et al; ARISTOTLE data from 32 large clinical trials. Int J Epidemiol. ischemic attack according to pretreatment risk for and RE-LY Investigators. The novel 2016;45(6):2075-2088. stroke or myocardial infarction [published online biomarker-based ABC (age, biomarkers, clinical September 18, 2017]. JAMA Neurol. doi:10.1001 history)-bleeding risk score for patients with atrial 8. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, /jamaneurol.2017.2136 fibrillation: a derivation and validation study. Lancet. Hayward RA. Assessing and reporting 2016;387(10035):2302-2311. heterogeneity in treatment effects in clinical trials: 11. Poli D, Antonucci E, Pengo V, Testa S, Palareti G. a proposal. Trials. 2010;11:85. Comparison of HAS-BLED and HAS-BED versus 14. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, CHADS and CHA DS VASC stroke and bleeding Ovbiagele B. Low glomerular filtration rate and risk 2 2 2 9. Burke JF, Hayward RA, Nelson JP, Kent DM. scores in patients with atrial fibrillation. Am J Cardiol. of stroke: meta-analysis. BMJ. 2010;341:c4249. Using internally developed risk models to assess 2017;119(7):1012-1016. heterogeneity in treatment effects in clinical trials. 15. Davidoff F. Can knowledge about heterogeneity Circ Cardiovasc Qual Outcomes. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Demystifying Neurosarcoidosis and Informing Prognosis

JAMA Neurology , Volume 74 (11) – Nov 9, 2017

Loading next page...
 
/lp/american-medical-association/demystifying-neurosarcoidosis-and-informing-prognosis-00oUhmePxh
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2017.1473
Publisher site
See Article on Publisher Site

Abstract

Opinion Editorial heterogeneity: re-analysis of individual participant hydrochloride therapy after stroke or transient 13. Hijazi Z, Oldgren J, Lindbäck J, et al; ARISTOTLE data from 32 large clinical trials. Int J Epidemiol. ischemic attack according to pretreatment risk for and RE-LY Investigators. The novel 2016;45(6):2075-2088. stroke or myocardial infarction [published online biomarker-based ABC (age, biomarkers, clinical September 18, 2017]. JAMA Neurol. doi:10.1001 history)-bleeding risk score for patients with atrial 8. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, /jamaneurol.2017.2136 fibrillation: a derivation and validation study. Lancet. Hayward RA. Assessing and reporting 2016;387(10035):2302-2311. heterogeneity in treatment effects in clinical trials: 11. Poli D, Antonucci E, Pengo V, Testa S, Palareti G. a proposal. Trials. 2010;11:85. Comparison of HAS-BLED and HAS-BED versus 14. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, CHADS and CHA DS VASC stroke and bleeding Ovbiagele B. Low glomerular filtration rate and risk 2 2 2 9. Burke JF, Hayward RA, Nelson JP, Kent DM. scores in patients with atrial fibrillation. Am J Cardiol. of stroke: meta-analysis. BMJ. 2010;341:c4249. Using internally developed risk models to assess 2017;119(7):1012-1016. heterogeneity in treatment effects in clinical trials. 15. Davidoff F. Can knowledge about heterogeneity Circ Cardiovasc Qual Outcomes.

Journal

JAMA NeurologyAmerican Medical Association

Published: Nov 9, 2017

References